Dr. Uri Weinberg currently serves as Novocure’s Chief Innovation Officer. In this role, Dr. Weinberg is responsible for expanding the innovative potential of Tumor Treating Fields (TTFields) therapy by developing real world evidence and its use, creating a regulatory framework for a blanket TTFields therapy indication, generating and testing new product development ideas and expanding the use of TTFields beyond oncology. Since joining Novocure in 2008, he has held several positions throughout his tenure with the company. Dr. Weinberg managed Novocure’s first clinical trial in lung cancer as well as the EF-14 clinical trial in newly diagnosed glioblastoma and built the company’s global Clinical Operations team in Switzerland. Most recently, he held the position of Chief Science Officer, where he oversaw early-stage research and development as well as the design and development stages of all clinical trials. Dr. Weinberg holds an M.D. Ph.D. from the Technion – Israel Institute of Technology.